Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for obesity and various metabolic disorders with an endocrinologistTicker(s): VKTX
- Assistant Professor of Medicine in the Division of Endocrinology at Columbia University.
- Manages over 200 patients with obesity and diabetes.
- Research expertise in the area of the central regulation of energy balance and metabolism and in the management of pituitary diseases; clinical practice includes neuroendocrinology, reproductive endocrinology, menopause, and the management of weight and metabolic disorders.
Does a dual GLP-1/GIP Receptor Agonist have a clear benefit to you over semaglutide?
What are your thoughts and key take aways from the Phase 1 trial of VK2735?Added By: sara_admin
Please discuss if there are additional beneficial synergistic merits above and beyond the activity of each individual component.Added By: userad5df6c5
Do you think Viking Therapeutics plans to make an oral version of VK2735 is feasible?Added By: sara_admin
How would you rate your level of excitement for VK2735 on a scale from 1-10?(10 being the most excited)Added By: sara_admin
Is insurance coverage a big factor in starting patients on a dual GLP-1/GIP Receptor Agonist?Added By: sara_admin
How do you see the side effect profile? Would there be a differentially higher tolerance of side effects in diabetic patients vs. obese patients. Do you view a lower side effect profile (as suggested by the 2735 P1 data) as a major factor for patient compliance in the diabetic and/or obese patient population?Added By: malkmus
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.